An assessment of the therapeutic potential of azapropazone in rheumatoid arthritis.
A trial to compare the therapeutic potential of 1200 mg. azapropazone daily with 3.9 g. aspirin daily was carried out in 108 out-patients with rheumatoid arthritis over a 14-day period. Analysis of results from the 85 patients with completed assessment data (49 on azapropazone; 36 on aspirin) showed that azapropazone was better than aspirin from the point of view of pain relief, number of days patients were withdrawn prematurely from the trial, and patient satisfaction with treatment. The differences, however, were not statistically significant. The authors compare the results obtained in this trial with those obtained previously from trials with 13 other antirheumatic drugs using the same method.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001032:Apazone / Q000008:administration & dosage / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001241:Aspirin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D006801:Humans; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy; D010342:Patient Acceptance of Health Care; D012075:Remission, Spontaneous; D014227:Triazines / Q000627:therapeutic use*
D014227:Triazines; D001032:Apazone; D001241:Aspirin